Bacha, Jeffrey A.;Steinø, Anne;Delmar Pharmaceuticals, Inc.;Brown, Dennis M.
发明人:
申请号：
EP16793533.7
公开号：
EP3294284A4
申请日:
2016.05.12
申请国别(地区):
EP
年份:
2019
代理人:
摘要：
The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (NSCLC) and ovarian cancer, as well as other types of malignancy, including brain metastases of NSCLC. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors； the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents and can possess additive or super-additive effects.
